1 nts who did not respond received doxorubicin/cytoxan.

2 , 5-FU, gemcitabine, docetaxel, oxaliplatin, cytoxan and cisplatin, and a majority of mice treated wi

3 he synovium of normal mice when treated with Cytoxan and this was associated with increased clinical

4 the major constituent of the anticancer drug Cytoxan, as well as other compounds that are activated b

5 the standard therapy using cyclophosphamide (Cytoxan; Bristol-Myers Squibb Co) in combination with ci

6 ratumoral delivery of HMGN1 with low dose of Cytoxan cured mice bearing small (slashed circle approxi

7 Intratumoral delivery of HMGN1 and R848 plus Cytoxan eradicated large established CT26 tumors.

8  with EPOCH (etoposide, prednisone, Oncovin, Cytoxan, hydroxydaunorubicin) infusional chemotherapy.

9 of paclitaxel to adjuvant AC (Adriamycin and Cytoxan) improves survival in patients with operable nod

10                                              Cytoxan in this regimen could be replaced by anti-CTLA4)

11  before and 1 week into a 3-month adriamycin/cytoxan neoadjuvant chemotherapy regimen can predict fin

12 stine, bischloroethylnitrosourea, melphalan, cytoxan, prednisone (VBMCP) and were treated on one of 3

13 -BMT conditioning regimen, cyclophosphamide (Cytoxan(R)) (Cy) and total body irradiation, were analyz